A retrospective study assesses the pancreatic immune-inflammation value's impact on breast cancer prognosis, highlighting racial disparities.
Key Points
This research aims to evaluate the variation of the Pan-Immune-Inflammatory-Value (PIV) across breast cancer subtypes and its prognostic significance with a focus on racial differences.
Conducted a retrospective review of data from 2,597 breast cancer patients treated from 2012 to 2022.
Calculated PIV as a composite of neutrophils, monocytes, lymphocytes, and platelets.
Performed comparative analysis using Mann-Whitney tests, ROC curves, and multivariable Cox regression for survival analysis.
Analyzed associations between PIV, race, subtype, and disease outcomes.
PIV levels significantly varied by race and subtype; Black women had lower high PIV odds compared to White women (OR = 0.595).
High PIV was associated with worse disease-free survival (DFS) and overall survival (OS) in the overall cohort (p < 0.0005).
In subgroup analysis, high PIV predicted shorter DFS in both racial groups but was not significant for OS in Black women or DFS in TNBC patients.
Multivariable analysis indicated that both stage and PIV independently predicted DFS and OS outcomes.